Search Results

Seattle Children’s Research Institute, the research division of Seattle Children’s Hospital and renowned global leader in pediatric research, and Genezen, a leading gene and cell therapy contract development and manufacturing organization, have unveiled a strategic manufacturing partnership for Seattle Children’s Research Institute’s X-linked agammaglobulinemia program.

Such a change would put the U.S. more in line with guidance in other countries and with the World Health Organization, which recommends one dose for children and adolescents only if they have comorbidities.

Recce Pharmaceuticals Ltd announced the continuation of work within its Anti-Infective Research Unit at the Murdoch Children’s Research Institute, to streamline its ongoing preclinical programs while investigating new indications for future clinical trials.

With pediatric inflammatory bowel disease diagnoses on the rise globally, a clinical trial in Seattle aims to transform treatment approaches through deep molecular profiling.

In a video posted to social media on Tuesday, HHS Secretary Robert F. Kennedy, Jr. claimed that there is a lack of clinical data to support the repeat COVID-19 booster strategy in children.